GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today reported its ...

Market Cap: Approximately $12 million. Crown Medical Collections: Estimated to collect at least $50 million net from $150 million in uncollected COVID testing claims. BE-Smart Esophageal Cancer Test: ...

Pharmaloz Manufacturing continues to add new customers. Projects accelerating growth in H2 2024. Aggressively pursuing strategic alternatives, including a potential sale. Nebula Genomics’ major new ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2025 Earnings Call Transcript November 19, 2025 ProPhase Labs, Inc. misses on earnings expectations. Reported EPS is $-0.16463 EPS, expectations were $-0.11.

How Strong Is ProPhase Labs' Balance Sheet? According to the last reported balance sheet, ProPhase Labs had liabilities of US$16.7m due within 12 months, and liabilities of US$13.1m due beyond 12 ...

ProPhase Labs (PRPH) announced that its three COVID-19 testing laboratory companies filed for reorganization under Chapter 11 in United States Bankruptcy Court for the District of New Jersey, ...

UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a diversified diagnostics, genomics, and consumer healthcare company, today reported ...

Company sees significant momentum in Pharmaloz, Nebula Genomics and ProPhase BioPharma Pharmaloz Manufacturing plans on track to increase capacity from $10 million to over $75 million in 2024 ...